Evolution of platinum resistance in high-grade serous ovarian cancer

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1169-1174

  Cooke, Susanna L ^a   Brenton, James D ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; PLATINUM COMPLEX;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CELL SUBPOPULATION; DRUG RESPONSE; HUMAN; NONHUMAN; NOTE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION;

DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; TIME FACTORS; TREATMENT FAILURE;

EID: 81255137064     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70123-1     Document Type: Note

References (55)

1. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232.
2. Dubeau L The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008, 9:1191-1197.
3. Levanon K, Crum C, Drapkin R New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008, 26:5284-5293.
4. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221:49-56.
5. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
6. Na YJ, Farley J, Zeh A, et al. Ovarian cancer: markers of response. Int J Gynecol Cancer 2009, 19(suppl 2):S21-S29.
7. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30:230-236.
8. Tan DS, Agarwal R, Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006, 7:925-934.
9. Gorringe KL, Jacobs S, Thompson ER, et al. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007, 13:4731-4739.
10. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007, 25:3985-3990.
11. Markman M, Hoskins W Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992, 10:520-528.
12. Bookman MA Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4:87-94.
13. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903.
14. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008, 26:20-25.
15. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011, 121:353-357.
16. Venkitaraman AR Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
17. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002, 94:61-67.
18. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002, 94:1396-1406.
19. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-574.
20. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995, 9:439-443.
21. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
22. Lim SL, Smith P, Syed N, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer 2008, 98:1452-1456.
23. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003, 115:523-535.
24. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. The Cancer Genome Atlas Research Network.
25. Borst P, Rottenberg S, Jonkers J How do real tumors become resistant to cisplatin?. Cell Cycle 2008, 7:1353-1359.
26. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
27. Swisher EM, Sakai W, Karlan BY, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008, 68:2581-2586.
28. Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009, 69:6381-6386.
29. Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007, 104:12117-12122.
30. Luria SE, Delbruck M Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
31. Klein M, Kimmelman LJ The role of spontaneous variants in the acquisition of streptomycin resistance by the shigellae. J Bacteriol 1946, 52:471-479.
32. Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007, 110:632-639.
33. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
34. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
35. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
36. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
37. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
38. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
39. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
40. Cooke SL, Ng CK, Melnyk N, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010, 29:4905-4913.
41. Iwasa Y, Nowak MA, Michor F Evolution of resistance during clonal expansion. Genetics 2006, 172:2557-2566.
42. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
43. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
44. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360:505-515. The International Collaborative Ovarian Neoplasm (ICON) Group.
45. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36:207-211.
46. Goss PE, Chambers AF Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer 2010, 10:871-877.
47. Dean M, Fojo T, Bates S Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
48. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
49. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
50. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
51. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
52. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
53. Etemadmoghadam D, deFazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009, 15:1417-1427.
54. Turner N, Tutt A, Ashworth A Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
55. Spruck CH, Won KA, Reed SI Deregulated cyclin E induces chromosome instability. Nature 1999, 401:297-300.